Preclinical combination therapy with gemcitabine and mechanisms of resistance

Seminars in Oncology

Volumn 23, Issue 5 SUPPL. 10, 1996, Pages 16-24

  Peters, G J ^a   Van Haperen, V W T R ^a   Bergman, A M ^a   Veerman, G ^a   Smitskamp Wilms, E ^a   Van Moorsel, C J A ^a   Kuiper, C M ^a   Braakhuis, B J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; CYTARABINE; DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOTIDE; DNA; DNA POLYMERASE; EXONUCLEASE; FLOXURIDINE DERIVATIVE; GEMCITABINE; NUCLEIC ACID; OXYGEN; PROTEIN; RIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; RNA POLYMERASE; SYNTHETASE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CROSS LINKING; DNA REPAIR; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DNA DAMAGE; DRUG RESISTANCE; HUMANS;

EID: 0029808528     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)